Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy in B-Cell Lymphomas: Current Status and Future Directions

作者：Julio C. Chávez, Farah Yassine, Jose Sandoval‐Sus, Mohamed A. Kharfan‐Dabaja · 发表于：International Journal of Hematologic Oncology · 年份：2021 · DOI：10.2217/ijh-2020-0021 · 被引用次数：15 · 研究领域：CAR-T cell therapy research、Lymphoma Diagnosis and Treatment、Cutaneous lymphoproliferative disorders research

AIMS: To review recent data and relevant of the role of anti-CD19 chimeric antigen receptor (CAR) T-cell therapy for B-cell non-Hodgkin lymphoma (NHL). METHODS: Review and compilation of the most recent and relevant data published in full text and abstract forms of anti-CD19 CAR T-cell therapy for B-cell NHL. RESULTS: Different anti-CD19 CAR T-cell therapy products have been tested and shown significant clinical activity across B-cell NHL patients. The objective responses in relapsed DLBCL, FL and MCL were 50-83%, 83-93% and 93%, respectively. CONCLUSIONS: Anti-CD19 CAR T-cell therapy is a viable option for poor risk refractory B-cell NHLs.